Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer | Zendy

Livia Lamartina | Zendy; Serena Ippolito | Zendy; Marion Danis | Zendy; François Bidault | Zendy; Isabelle Borget | Zendy; A. Berdelou | Zendy; Abir Al Ghuzlan | Zendy; Dana M. Hartl | Zendy; Pierre Blanchard | Zendy; M. Terroir | Zendy; Désirèe Deandreis | Zendy; Martin Schlumberger | Zendy; Éric Baudin | Zendy; Sophie Leboulleux | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer

Author(s) -

Livia Lamartina,

Serena Ippolito,

Marion Danis,

François Bidault,

Isabelle Borget,

A. Berdelou,

Abir Al Ghuzlan,

Dana M. Hartl,

Pierre Blanchard,

M. Terroir,

Désirèe Deandreis,

Martin Schlumberger,

Éric Baudin,

Sophie Leboulleux

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-4391

Subject(s) - medicine , common terminology criteria for adverse events , neck dissection , thyroidectomy , radiation therapy , thyroid cancer , adverse effect , gastroenterology , airway , surgery , oncology , cancer , thyroid , radiology

Antiangiogenic tyrosine kinase inhibitors (TKIs) are the mainstay of advanced thyroid cancer (TC) treatment. Concern is rising about TKI-related toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research